用于评估药物诱导的特异性肝损伤因果关系的方法
Miren García-Cortés1,2, Gonzalo Matilla-Cabello1,2, M Isabel Lucena1,2,3
1Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA, Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
概括
诊断药物诱导性肝损伤 (DILI) 是复杂的. 像RECAM和生物标志物研究这样的新方法旨在提高DILI的准确性和个性化患者护理.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
- 生物标志物发现发现
背景情况:
- 异常药物诱导性肝损伤 (DILI) 由于非特异性临床特征而带来诊断挑战.
- 准确的DILI诊断需要全面的临床,药理和实验室数据来排除其他肝脏疾病.
研究的目的:
- 审查目前的诊断挑战和评估药物诱导肝损伤的不断发展的方法.
- 强调因果关系评估工具的进步和DILI研究的未来方向.
主要方法:
- 对DILI现有的诊断标准和因果关系评估工具的审查.
- 讨论新出现的方法,包括电子因果关系评估方法 (RECAM).
- 探索国际网络和基于患者的体外实验方法的作用.
主要成果:
- 标准化方法如罗塞尔·乌克拉夫因果关系评估方法 (RUCAM) 和专家意见被广泛使用.
- 修订后的RECAM显示了作为未来RUCAM的替代品的希望.
- 生物标志物研究和新的体外试验方法正在推动DILI诊断.
结论:
- 改善DILI诊断需要采用多方面的方法,将临床评估与先进的评估工具相结合.
- 持续的研究和协作努力对于开发更精确的诊断策略至关重要.
- DILI诊断的未来在于个性化医疗方法,得到验证的生物标志物和体外模型的帮助.
相关概念视频
Pharmacovigilance
797
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
797
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34
Nonlinear Pharmacokinetics: Causes of Nonlinearity
151
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
151
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Drug Concentration Versus Time Correlation
690
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
690
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K


